Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Department of Neurology and Neurosurgery, University Medical Centre Utrecht, Utrecht, The Netherlands.
Eur J Neurol. 2023 Oct;30(10):3244-3255. doi: 10.1111/ene.15979. Epub 2023 Jul 21.
Meningiomas are the most common primary tumours of the central nervous system. This study aimed to provide comprehensive nationwide estimates on the incidence, prevalence and prognostic impact of meningioma diagnosis in the Netherlands.
Adult patients diagnosed with meningioma in 2000-2019 were selected from the Dutch Brain Tumour Registry (DBTR), part of the Netherlands Cancer Registry (NCR). Time trends in age-adjusted incidence and prevalence rates were evaluated using the estimated annual percentage change (EAPC). Relative survival rates were calculated using the Pohar Perme estimator. Case completeness of the DBTR/NCR was estimated through record linkage with one of the Dutch neuro-oncology centres.
From a total of 23,454 cases of meningioma, 11,306 (48.2%) were histologically confirmed and 12,148 (51.8%) were radiological diagnoses. Over time, the incidence of diagnosis increased from 46.9 per 1,000,000 inhabitants (European Standardized Rate [ESR]) to 107.3 (EAPC 4.7%, p < 0.01), with an increase in the incidence of radiological diagnoses from 14.0 to 70.2 per 1,000,000 ESR (EAPC 9.1%, p < 0.01). The prevalence of meningioma was estimated at 1012/1,000,000 on 1 January 2020, with almost 17,800 individuals having had a diagnosis of meningioma. Relative survival rate at 10 years for grade 1 meningiomas was 91.0% (95% confidence interval [CI] 89.4%-92.3%), 71.3% (95% CI 66.8%-75.2%) for grade 2 meningiomas and 36.4% (95% CI 27.3%-45.6%) for grade 3 meningiomas. Local case completeness was estimated at 97.6% for histologically confirmed meningiomas and 84.5% for radiological diagnoses.
With a near-complete registry, meningioma prevalence was estimated at over 1000 per 1,000,000 inhabitants.
脑膜瘤是中枢神经系统最常见的原发性肿瘤。本研究旨在提供荷兰脑膜瘤诊断发病率、患病率和预后影响的综合全国估计值。
从荷兰脑肿瘤登记处（DBTR）中选择 2000-2019 年期间诊断为脑膜瘤的成年患者，该登记处是荷兰癌症登记处（NCR）的一部分。使用估计的年百分比变化（EAPC）评估年龄调整后的发病率和患病率的时间趋势。使用 Pohar Perme 估计器计算相对生存率。通过与荷兰神经肿瘤学中心之一的记录链接来估计 DBTR/NCR 的病例完整性。
从总共 23454 例脑膜瘤中，11306 例（48.2%）为组织学证实，12148 例（51.8%）为影像学诊断。随着时间的推移，诊断发病率从 46.9/1000000 居民（欧洲标准化率 [ESR]）增加到 107.3（EAPC 4.7%，p<0.01），影像学诊断的发病率从 14.0 增加到 70.2/1000000 ESR（EAPC 9.1%，p<0.01）。2020 年 1 月 1 日，脑膜瘤的患病率估计为 1012/1000000，约有 17800 人被诊断为脑膜瘤。1 级脑膜瘤的 10 年相对生存率为 91.0%（95%置信区间 [CI] 89.4%-92.3%），2 级脑膜瘤为 71.3%（95% CI 66.8%-75.2%），3 级脑膜瘤为 36.4%（95% CI 27.3%-45.6%）。组织学证实的脑膜瘤的局部病例完整性估计为 97.6%，影像学诊断的病例完整性估计为 84.5%。
基于近乎完整的登记处，脑膜瘤的患病率估计超过 1000/1000000 居民。
